Cell Bio Human Tech Co.,Ltd
Financials
Valuation Metrics
Cell Bio Human Tech Co.,Ltd's Market Cap is ₩679B. At end of 2025 it was ₩763B. Ranked #1567 of 2,421 in KR market (top 65%), #923 of 1,640 on KOSDAQ (top 56%), #182 of 294 in Materials (top 62%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 67.88B KRW | KR#1,567/2,421 Sec#182/294 |
| Revenue | 60.90B KRW | KR#1,693/2,421 Sec#241/294 |
| Net Income | 10.46B KRW | KR#956/2,421 Sec#110/294 |
| Total Assets | 92.01B KRW | KR#1,846/2,421 Sec#250/294 |
| Net Assets | 63.58B KRW | KR#1,751/2,421 Sec#238/294 |
| Employees | 58 | KR#1,984/2,421 Sec#248/294 |
| Value | ||
| P/E | 6.49x | KR#504/2,421 Sec#67/294 |
| P/B | 1.07x | KR#1,522/2,421 Sec#237/294 |
| PEG | 0.08x | KR#389/2,421 Sec#42/294 |
| P/S | 1.11x | KR#1,447/2,421 Sec#240/294 |
| EV/EBITDA | 7.91x | KR#466/2,421 Sec#56/294 |
| FCF Yield | -7.59% | KR—/2,421 Sec—/294 |
| Profitability | ||
| ROE | 16.45% | KR#259/2,421 Sec#18/294 |
| ROA | 11.37% | KR#213/2,421 Sec#14/294 |
| Op. Margin | 16.05% | KR#266/2,421 Sec#17/294 |
| Revenue Growth | 61.93% | KR#153/2,421 Sec#8/294 |
| Earnings Growth | 76.87% | KR#444/2,421 Sec#51/294 |
| Financial Health | ||
| Debt Ratio | 44.71% | KR#886/2,421 Sec#103/294 |
| Total Debt | 20.42B KRW | KR#1,375/2,421 Sec#209/294 |
| FCF | -5.15B KRW | KR#1,500/2,421 Sec#181/294 |
| Cash | 11.00B KRW | KR#1,641/2,421 Sec#199/294 |
| Current Ratio | 2.87x | KR#594/2,421 Sec#62/294 |
| Net Debt/EBITDA | 0.96x | KR#730/2,421 Sec#72/294 |
| Performance | ||
| 1Y Return | -22.74% | KR#1,343/2,421 Sec#183/294 |
| 1M Return | 18.21% | KR#274/2,421 Sec#27/294 |
| From 52W High | -35.09% | KR#709/2,421 Sec#100/294 |
| 1Y MDD | -52.64% | KR#1,107/2,421 Sec#161/294 |
| Trading | ||
| Volume | 94,683 shares | KR#806/2,421 Sec#70/294 |
| Trading Value | 697.2M KRW | KR#826/2,421 Sec#77/294 |
| Foreign Own. | 4.08% | KR#1,030/2,421 Sec#117/294 |
| Per Share | ||
| EPS | 1,120 KRW | KR#679/2,421 Sec#82/294 |
| BPS | 6,809 KRW | KR#1,263/2,421 Sec#191/294 |
Company Info
CellBioHumanTech was established in 2015 and listed on the KOSDAQ market in 2023. The company develops, manufactures, and supplies mask pack materials such as PT CELL, SEMI GEL, S Cell, and NC Cell, and is expanding into patches and wound dressings. It achieves cost savings and quality enhancement by directly producing non-woven fabrics at its Vietnam local subsidiary. CellBioHumanTech is expanding its global market presence through new material development and pursuing entry into the medical field with wound dressing development. CellBioHumanTech is headquartered in Anyang-si, Gyeonggi-do.